Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Increased risk of lymphoma in patients with ulcerative colitis treated With thiopurines

A study in the most recent issue of Gastroenterology examines the risk of lymphoma in patients with ulcerative colitis treated with thiopurines.

News image

There is controversy over whether the treatment of patients with ulcerative colitis with thiopurines increases their risk of lymphoma.

Dr Nabeel Khan and colleagues from Louisiana, USA evaluated the risk of lymphoma among thiopurine-treated patients with ulcerative colitis.

The researchers obtained nationwide data from the Veterans Affairs (VA) health care system from 2001 to 2011.

The team performed a retrospective cohort study, analyzing data on 36,891 patients from their date of diagnosis of ulcerative colitis in the VA health care system to a diagnosis of lymphoma or 2011.

Thiopurine exposure was assessed using the VA pharmacy database.

Incidence rates of lymphoma were 2.3 per 1000 person-years in those treated with thiopurines
Gastroenterology

Patients who developed lymphoma were identified based on ICD-9 codes and confirmed by manual chart review.

In total, 4734 patients with ulcerative colitis were treated with thiopurines for a median of 1 year.

The research team observed that lymphoma developed in 119 patients who had not been treated with thiopurines, 18 who were treated with thiopurines, and 5 who had discontinued treatment with thiopurines.

The incidence rates of lymphoma were 0.60 per 1000 person-years among patients who had not been treated with thiopurines, 2.3 among patients who were treated with thiopurines, and 0.28 among patients who had discontinued treatment with thiopurines.

The incidence rates of lymphoma during the first year, second year, third year, fourth year, and more than 4 years of thiopurine therapy were 0.9, 1.6, 1.6, 5, and 8.9 per 1000 person-years, respectively.

The age-, sex-, and race-adjusted hazard ratios of developing lymphoma were 4.2 while being treated with thiopurines, and 0.5 after discontinuing treatment with thiopurines compared with patients who had not been treated with thiopurines.

Dr Khan's team concludes, "Based on a retrospective, nationwide cohort study, patients with ulcerative colitis have a 4-fold increase in risk of lymphoma while being treated with thiopurines compared with patients who have not been treated with thiopurines."

"The risk increases gradually for successive years of therapy. Discontinuing thiopurine therapy reduces the risk of lymphoma."

Gastroenterology 2013: 145(5): 1007-1015.e3
30 October 2013

Go to top of page Email this page Email this page to a colleague

 02 March 2015

Advanced search
 02 March 2015 
Liver disease in patients awaiting liver transplant
 02 March 2015 
Assessment of GERD
 02 March 2015 
Genes and early diagnosis of IBD
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Prevalence of microscopic colitis
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
NAFLD and CVD
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents
 05 February 2015 
Thalidomide and refractory Crohn's
 04 February 2015 
Telemedicine in IBD
 04 February 2015 
Infliximab and muscle wasting in Crohn's
 04 February 2015 
Resistance mutations in chronic Hep B
 03 February 2015 
Testosterone in advanced liver disease
 03 February 2015 
Mortality in peptic ulcer bleeding
 03 February 2015 
Colonoscopic remission of ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us